Document Detail


An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group.
MedLine Citation:
PMID:  11057351     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To compare emedastine ophthalmic solution 0.05% BID to levocabastine ophthalmic suspension 0.05% BID in reducing chemosis, eyelid swelling and other signs and symptoms in subjects with seasonal allergic conjunctivitis. METHODS: In a randomized, double-masked, parallel controlled study, emedastine ophthalmic solution 0.05% BID was compared to levocabastine ophthalmic suspension 0.05% BID for control of chemosis, eyelid swelling and other parameters in the environmental allergy study model. RESULTS: At Days 7, 14, 30 and 42, emedastine was significantly better than levocabastine at controlling chemosis and eyelid swelling (p < 0.05). A statistical trend was seen at Day 3 (0.05 < p < 0.10). Results were clinically relevant at Days 30 and 42. Emedastine was also significantly better at reducing redness and itching at Days 7, 14, 30 and 42 (p < 0.05). CONCLUSION: Emedastine is more efficacious than levocabastine in reducing chemosis, eyelid swelling and other efficacy variables associated with seasonal allergic conjunctivitis.
Authors:
A Secchi; A Leonardi; M Discepola; J Deschenes; M B Abelson
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Acta ophthalmologica Scandinavica. Supplement     Volume:  -     ISSN:  1395-3931     ISO Abbreviation:  Acta Ophthalmol Scand Suppl     Publication Date:  2000  
Date Detail:
Created Date:  2001-01-31     Completed Date:  2001-02-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9516974     Medline TA:  Acta Ophthalmol Scand Suppl     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  48-51     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, University of Padua, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Benzimidazoles / administration & dosage,  adverse effects,  therapeutic use*
Child
Child, Preschool
Conjunctiva / drug effects
Conjunctivitis, Allergic / drug therapy*,  pathology
Double-Blind Method
Edema / drug therapy*,  pathology
Eyelid Diseases / drug therapy*,  pathology
Female
Histamine H1 Antagonists / administration & dosage,  adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Ophthalmic Solutions
Piperidines / administration & dosage,  adverse effects,  therapeutic use*
Safety
Seasons
Treatment Outcome
Chemical
Reg. No./Substance:
0/Benzimidazoles; 0/Histamine H1 Antagonists; 0/Ophthalmic Solutions; 0/Piperidines; 79516-68-0/levocabastine; 87233-61-2/emedastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.0...
Next Document:  Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management ...